OS Therapies’ (OSTX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of OS Therapies (NYSE:OSTX) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $20.00 price objective on the stock.

Separately, Maxim Group increased their target price on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, January 16th.

OS Therapies Trading Down 10.1 %

NYSE OSTX opened at $1.70 on Thursday. The business’s 50-day moving average price is $3.28 and its 200 day moving average price is $3.13. OS Therapies has a twelve month low of $1.58 and a twelve month high of $7.00.

Insiders Place Their Bets

In other OS Therapies news, major shareholder Shalom Auerbach sold 16,720 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total transaction of $112,692.80. Following the transaction, the insider now owns 2,531,211 shares of the company’s stock, valued at $17,060,362.14. This trade represents a 0.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Institutional Trading of OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new stake in shares of OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.